567.56 USD
-4.3 (-0.75%)
567.56 USD
0 (0%)
MEDP gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. MEDP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. MEDP is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make MEDP suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year MEDP was profitable.
MEDP had a positive operating cash flow in the past year.
MEDP had positive earnings in each of the past 5 years.
Each year in the past 5 years MEDP had a positive operating cash flow.
1.2 Ratios
MEDP has a better Return On Assets (24.70%) than 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 147.46%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 91.45%, MEDP belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for MEDP is significantly above the industry average of 13.99%.
The 3 year average ROIC (38.75%) for MEDP is below the current ROIC(91.45%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROIC | 91.45% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
1.3 Margins
The Profit Margin of MEDP (18.36%) is better than 92.98% of its industry peers.
In the last couple of years the Profit Margin of MEDP has grown nicely.
The Operating Margin of MEDP (21.50%) is better than 89.47% of its industry peers.
In the last couple of years the Operating Margin of MEDP has grown nicely.
With a Gross Margin value of 31.11%, MEDP is not doing good in the industry: 70.18% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of MEDP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% |
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MEDP is creating value.
MEDP has less shares outstanding than it did 1 year ago.
MEDP has less shares outstanding than it did 5 years ago.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.02 indicates that MEDP is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.02, MEDP belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
There is no outstanding debt for MEDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.02 |
ROIC/WACC8.46
WACC10.81%
2.3 Liquidity
A Current Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
MEDP has a Current ratio of 0.57. This is amonst the worse of the industry: MEDP underperforms 94.74% of its industry peers.
A Quick Ratio of 0.57 indicates that MEDP may have some problems paying its short term obligations.
MEDP's Quick ratio of 0.57 is on the low side compared to the rest of the industry. MEDP is outperformed by 92.98% of its industry peers.
The current and quick ratio evaluation for MEDP is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 |
3. Growth
3.1 Past
MEDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.22%, which is quite impressive.
Measured over the past years, MEDP shows a very strong growth in Earnings Per Share. The EPS has been growing by 33.22% on average per year.
The Revenue has grown by 13.88% in the past year. This is quite good.
Measured over the past years, MEDP shows a quite strong growth in Revenue. The Revenue has been growing by 19.62% on average per year.
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
3.2 Future
The Earnings Per Share is expected to grow by 12.31% on average over the next years. This is quite good.
Based on estimates for the next years, MEDP will show a quite strong growth in Revenue. The Revenue will grow by 12.31% on average per year.
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 39.69, which means the current valuation is very expensive for MEDP.
Compared to the rest of the industry, the Price/Earnings ratio of MEDP is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.92. MEDP is valued slightly more expensive when compared to this.
MEDP is valuated quite expensively with a Price/Forward Earnings ratio of 33.76.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MEDP indicates a somewhat cheap valuation: MEDP is cheaper than 64.91% of the companies listed in the same industry.
MEDP's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.69 | ||
| Fwd PE | 33.76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MEDP is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, MEDP is valued cheaper than 80.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.62 | ||
| EV/EBITDA | 29.32 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of MEDP may justify a higher PE ratio.
A more expensive valuation may be justified as MEDP's earnings are expected to grow with 13.97% in the coming years.
PEG (NY)2.03
PEG (5Y)1.19
EPS Next 2Y15.37%
EPS Next 3Y13.97%
5. Dividend
5.1 Amount
No dividends for MEDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
567.56
-4.3 (-0.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners87.26%
Inst Owner Change-6.93%
Ins Owners0.37%
Ins Owner Change-6.92%
Market Cap15.99B
Revenue(TTM)2.36B
Net Income(TTM)433.00M
Analysts52.22
Price Target550.48 (-3.01%)
Short Float %6.06%
Short Ratio4.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.04%
Min EPS beat(2)2.57%
Max EPS beat(2)7.52%
EPS beat(4)4
Avg EPS beat(4)12.38%
Min EPS beat(4)2.57%
Max EPS beat(4)21.62%
EPS beat(8)8
Avg EPS beat(8)12.23%
EPS beat(12)11
Avg EPS beat(12)11.91%
EPS beat(16)15
Avg EPS beat(16)13.95%
Revenue beat(2)2
Avg Revenue beat(2)5.36%
Min Revenue beat(2)0.93%
Max Revenue beat(2)9.78%
Revenue beat(4)3
Avg Revenue beat(4)3.28%
Min Revenue beat(4)-1.63%
Max Revenue beat(4)9.78%
Revenue beat(8)3
Avg Revenue beat(8)0.43%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)0.68%
PT rev (3m)27.03%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)11.33%
EPS NY rev (1m)0.03%
EPS NY rev (3m)5.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)1.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.69 | ||
| Fwd PE | 33.76 | ||
| P/S | 6.78 | ||
| P/FCF | 23.62 | ||
| P/OCF | 22.48 | ||
| P/B | 54.45 | ||
| P/tB | N/A | ||
| EV/EBITDA | 29.32 |
EPS(TTM)14.3
EY2.52%
EPS(NY)16.81
Fwd EY2.96%
FCF(TTM)24.02
FCFY4.23%
OCF(TTM)25.25
OCFY4.45%
SpS83.72
BVpS10.42
TBVpS-14.29
PEG (NY)2.03
PEG (5Y)1.19
Graham Number57.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| ROCE | 108.09% | ||
| ROIC | 91.45% | ||
| ROICexc | 233.48% | ||
| ROICexgc | N/A | ||
| OM | 21.5% | ||
| PM (TTM) | 18.36% | ||
| GM | 31.11% | ||
| FCFM | 28.7% |
ROA(3y)18.14%
ROA(5y)15.16%
ROE(3y)54.33%
ROE(5y)40%
ROIC(3y)38.75%
ROIC(5y)29.27%
ROICexc(3y)71.87%
ROICexc(5y)52.56%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)47.22%
ROCE(5y)35.45%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y64.05%
ROICexc growth 5Y48.31%
OM growth 3Y6.82%
OM growth 5Y7.46%
PM growth 3Y6.48%
PM growth 5Y10.5%
GM growth 3Y2.7%
GM growth 5Y1.75%
F-Score8
Asset Turnover1.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.93% | ||
| Cap/Sales | 1.46% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 132.81% | ||
| Profit Quality | 156.3% | ||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 8.02 |
F-Score8
WACC10.81%
ROIC/WACC8.46
Cap/Depr(3y)142.96%
Cap/Depr(5y)144.54%
Cap/Sales(3y)2.07%
Cap/Sales(5y)2.41%
Profit Quality(3y)141.71%
Profit Quality(5y)142.32%
High Growth Momentum
Growth
EPS 1Y (TTM)25.22%
EPS 3Y37.96%
EPS 5Y33.22%
EPS Q2Q%28.24%
EPS Next Y19.51%
EPS Next 2Y15.37%
EPS Next 3Y13.97%
EPS Next 5Y12.31%
Revenue 1Y (TTM)13.88%
Revenue growth 3Y22.68%
Revenue growth 5Y19.62%
Sales Q2Q%23.74%
Revenue Next Year19.17%
Revenue Next 2Y15.52%
Revenue Next 3Y13.11%
Revenue Next 5Y12.31%
EBIT growth 1Y24.03%
EBIT growth 3Y31.04%
EBIT growth 5Y28.55%
EBIT Next Year28.34%
EBIT Next 3Y15.87%
EBIT Next 5Y14.69%
FCF growth 1Y79.18%
FCF growth 3Y34.54%
FCF growth 5Y25.47%
OCF growth 1Y71.92%
OCF growth 3Y32.23%
OCF growth 5Y24.7%
MEDPACE HOLDINGS INC / MEDP FAQ
What is the fundamental rating for MEDP stock?
ChartMill assigns a fundamental rating of 7 / 10 to MEDP.
What is the valuation status of MEDPACE HOLDINGS INC (MEDP) stock?
ChartMill assigns a valuation rating of 4 / 10 to MEDPACE HOLDINGS INC (MEDP). This can be considered as Fairly Valued.
How profitable is MEDPACE HOLDINGS INC (MEDP) stock?
MEDPACE HOLDINGS INC (MEDP) has a profitability rating of 9 / 10.
Can you provide the expected EPS growth for MEDP stock?
The Earnings per Share (EPS) of MEDPACE HOLDINGS INC (MEDP) is expected to grow by 19.51% in the next year.